Consolidated Balance Sheets - USD ($) $ in Millions		Dec. 31, 2024	Dec. 31, 2023
Assets
Cash and cash equivalents		$ 328	$ 400
Restricted cash and cash equivalents (Note 19)		37	501
Accounts receivable (Note 6)		123	137
Inventory, net (Note 8)		302	375
Derivative instruments (Notes 5 and 14)		66	89
Other current assets		184	52
Total current assets		1,040	1,554
Property, plant and equipment, net (Note 10)		3,154	3,839
Nuclear decommissioning trust funds (Notes 9 and 14)		1,724	1,575
Derivative instruments (Notes 5 and 14)		5	6
Other noncurrent assets		183	147
Total Assets		6,106	7,121
Liabilities and Equity
Long-term debt, due within one year (Notes 13 and 14)		17	9
Accrued interest		18	32
Accounts payable and other accrued liabilities		266	344
Derivative instruments (Notes 5 and 14)		0	32
Other current liabilities		154	69
Total current liabilities		455	486
Long-term debt (Notes 13 and 14)		2,987	2,811
Derivative instruments (Notes 5 and 14)		7	11
Postretirement benefit obligations (Note 15)		305	368
Asset retirement obligations and accrued environmental costs (Note 11)		468	469
Deferred income taxes (Note 7)		362	407
Other noncurrent liabilities		135	35
Total Liabilities		4,719	4,587
Commitments and Contingencies (Note 12)
Stockholders’ Equity
Common stock	[1]	0	0
Additional paid-in capital		1,725	2,346
Accumulated retained earnings (deficit)		(326)	134
Accumulated other comprehensive income (loss)		(12)	(23)
Total Stockholders' Equity		1,387	2,457
Noncontrolling interests		0	77
Total Equity		1,387	2,534
Total Liabilities and Equity		$ 6,106	$ 7,121

[1] (a)45,961,910 and 59,028,843 shares issued and outstanding as of December 31, 2024 (Successor) and December 31, 2023 (Successor), respectively.